Project to redesign UK pharma supply chain moves into technology application phase

25 August 2015
gsk-location-big

A major project to redesign the UK’s pharma supply chain has moved into the next phase following £11.2 million ($17.7 million) of government funding,

The REMEDIES project was launched in 2014 and headed by GlaxoSmithKline (LSE: GSK) with research led by the University of Cambridge’s Institute for Manufacturing. It is due to be completed in March 2018 and has several technology-based projects underpinned by two platform projects: clinical trials supply chains led by GSK and commercial supply chains led by the Institute for Manufacturing. The announcement of the new government funding, and a further £11 million from industry means that expenditures can now be approved and the project will move into the technology application phase.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical